<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611972</url>
  </required_header>
  <id_info>
    <org_study_id>1243331</org_study_id>
    <secondary_id>K12HD051958</secondary_id>
    <secondary_id>UL1TR001860</secondary_id>
    <nct_id>NCT03611972</nct_id>
  </id_info>
  <brief_title>Sucrose-sweetened Beverage in African-American and Caucasian Women.</brief_title>
  <acronym>SAAC</acronym>
  <official_title>Effects of Sucrose-sweetened Beverage in African-American and Caucasian Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this pilot study is to measure changes in metabolic risk factors of
      cardiovascular disease and type 2 diabetes in response to sugar-sweetened beverages in
      African-American and non-Hispanic white women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dietary intervention during which participants will consume a SSB daily, with each
      meal for two weeks. At the beginning and end of the two-week intervention, participants will
      have blood drawn under fasting and postprandial (after a meal) conditions for the measurement
      of lipid risk factors associated with cardiovascular disease. Participants will also undergo
      an oral glucose tolerance test (OGTT) to assess insulin sensitivity. All sugar-sweetened
      beverages will be provided.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dietary intervention</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All outcomes measures are analyzed using only the participant's study ID number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting and postprandial plasma triglycerides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting and postprandial plasma cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein (LDL)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting and postprandial plasma low-density lipoprotein (LDL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Participants will drink a beverage containing 75g of glucose and blood will be drawn before the drink and at 30 minutes, 60 minutes, 90 minutes, 120 minutes and 180 minutes after the drink. Plasma glucose and insulin will be measured at each time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>2 weeks</time_frame>
    <description>Waist circumference</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sugar-sweetened beverage (SSB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugar-sweetened beverage</intervention_name>
    <description>Sugar-sweetened koolaid-flavored water.</description>
    <arm_group_label>Sugar-sweetened beverage (SSB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 25 - 35 kg/m2

        Exclusion Criteria:

          -  Does not identify as African-American or non-hispanic White

          -  Glucose intolerance (fasting glucose &gt;100 mg/dl)

          -  Evidence of liver disorder (AST or ALT &gt;200% upper limit of normal range)

          -  Evidence of kidney disorder (&gt;2.0mg/dl creatinine)

          -  Evidence of thyroid disorder (out of normal range)

          -  Systolic blood pressure consistently over 140mmHg or diastolic blood pressure over
             90mmHg

          -  Triglycerides &gt; 150mg/dl

          -  LDL-C &gt; 130mg/dl

          -  Hemoglobin &lt; 8.5 g/dL

          -  Pregnant or lactating women

          -  Current, prior (within 12 months), or anticipated use of any hypolipidemic or
             anti-diabetic agents PROTOCOL TITLE: The Effects of Sucrose Beverage on
             African-American and Caucasian Women (SAAC) Study Page 4 of 18 Revised: November 27,
             2013

          -  Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any
             other medication which, in the opinion of the investigator, may confound study results

          -  Use of chronic corticosteroids (everyday use for a month or longer)

          -  Use of tobacco

          -  Strenuous exerciser (&gt;3.5 hours/week at a level more vigorous than walking)

          -  Surgery for weight loss

          -  Diet exclusions: Food allergies, special dietary restrictions, food allergies, routine
             consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened
             beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu

          -  Veins that are assessed by the CCRC R.N.s as being unsuitable for long-term infusions
             and multiple blood draws from a catheter

          -  Any other condition that, in the opinion of the investigators, would put the subject
             at risk

          -  We will exclude individuals from each of the following special populations:

               -  Adults unable to consent

               -  Individuals who are not yet adults (infants, children, teenagers &lt; 18 years)

               -  Pregnant women

               -  Prisoners
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candice Price, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candice Price, PhD</last_name>
    <phone>530-752-5379</phone>
    <email>caaprice@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Price, PhD</last_name>
      <phone>530-752-5379</phone>
      <email>caaprice@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis CTSC Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Kain, RN, MSN, CNL</last_name>
      <phone>916-703-5595</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

